Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study

DONGDONG WANG1*, XIAO CHEN1,2* and ZHIPING LI1

1Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102;
2Department of Pharmacy, The People's Hospital of Jiangyin, Jiangyin, Jiangsu 214400, P.R. China

Received October 16, 2018; Accepted June 11, 2019

DOI: 10.3892/ol.2019.10562

Abstract. Numerous studies have established population pharmacokinetics (PPK) models of sirolimus in various populations. However, a PPK model of sirolimus in Chinese patients with pediatric kaposiform hemangioendothelioma (PKHE) has yet to be established; therefore, this was the purpose of the present study. The present study was a retrospective analysis that utilized the trough concentration data obtained from traditional therapeutic drug monitoring-based dose adjustments. A total of 17 Chinese patients with PKHE from a real-world study were characterized by non-linear mixed-effects modeling. The impact of demographic features, biological characteristics and concomitant medications was assessed. The developed final model was evaluated via bootstrap and a prediction-corrected visual predictive check. A one-compartment model with first-order absorption and elimination was used for modeling of data for PKHE. The typical values of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) in the final model were 3.19 l/h and 165 liters, respectively. Age, alanine transaminase levels and sex were included as significant covariates for CL/F, while the duration of treatment with sirolimus was a significant covariate for V/F. In conclusion, the present study developed and validated the first sirolimus PPK model for Chinese patients with PKHE.

Introduction

Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor type with a prevalence of 0.9/100,000 children between 1991 and 2009 in the USA (1). It affects the head/neck region, the extremities and the trunk, and even occurs in the retroperitoneal or thoracic cavity, with invasion of the skin, subcutaneous fat and muscle (2). KHE triggers pain and causes deformity. Additionally, this local aggressive lesion may cause platelet trapping, leading to profound thrombocytopenia, an enlarged lesion and a consumptive coagulopathy with significant hypofibrinogenemia, in a process termed Kasabach-Merritt phenomenon (KMP) (3). While KHE is a benign lesion type, KMP poses a significant threat to the life of affected patients, and the mortality rate was as high as 12-30% between 1991 and 2009 due to various factors, including local invasion, hemodynamic instability and compression of vital structures (4,5). Therefore, it is necessary to develop treatments for KHE.

Various studies have described that sirolimus, an inhibitor of mTOR, is a treatment option for KHE (6-10). However, sirolimus exhibits considerable inter- and intra-individual variabilities in its pharmacokinetics (PK), with a poor association between the drug dosage and blood concentrations, which makes it difficult to specify an optimal dose (11,12).

Population pharmacokinetics (PPK) collects PK information from sparse data on patients (13,14). PPK analysis is able to distinguish inter-individual variability and residual unexplained confounders (15). Therefore, PPK has a greater statistical power for verifying the effect of multiple factors on the PK of sirolimus compared with that of traditional PK analysis (16), making it possible to define an optimal dose schedule.

However, the sirolimus PPK model in Chinese patients with pediatric KHE (PKHE), to the best of our knowledge, remains undefined. The objective of the present study was to establish a PPK model for sirolimus in a Chinese PKHE population, and to identify factors that account for the PK variability, in order to optimize individualized therapy.

Materials and methods

Patients and data collection. Data for a total of 17 Chinese patients with PKHE (11 males and 6 females; age, 0.2-6 years; mean age, 1.2±1.2 years) who presented at the Children's Hospital of Fudan University between January 2016 and April 2018, were retrospectively analyzed. Data on the drug concentrations and relevant clinical information were obtained from therapeutic drug monitoring (TDM) records and medical records, respectively. The present study was approved by the
Various statistical models (equations 2-4) describing the random residual variability were considered:

\[ Y = IPRED + \epsilon \]  
\[ Y = IPRED \times \exp (\epsilon) \]  
\[ Y = IPRED \times \exp (\epsilon_1) + \epsilon_2 \]

where \( Y \) represents the observation, \( IPRED \) is the individual predicted concentration and \( \epsilon_1 \) is symmetrically distributed, for zero-mean random variables with variance terms that are estimated as part of the population model fitting process. Based on the minimum objective function value (OFV), equation (3) was finally selected to calculate the residual variability.

**Covariate model.** In order to explain the variability of PK parameters, the associations among covariates and all the PK parameters were investigated. The potential covariates included sex, age, weight, DTT, DDS, ALT, AST, Cr, UR, HCT, HGB, MCH, MCHC and concomitant medications. The covariate model was set up in a stepwise manner (15). To compare hierarchical models, a likelihood ratio test was adopted. The change in OFV caused by the inclusion of a covariate is proportional to twice the negative log likelihood of the data and approximates a \( \chi^2 \) distribution. In the univariate analysis, a decrease in the OFV by \( >3.84 \) (\( P<0.05 \); degrees of freedom =1) was used as a criterion for inclusion of the covariate in the base model (15). The significant covariate-parameter associations were reserved in the model. When a full regression model was built, the model was further tested by dropping one covariate from each parameter at a time to acquire the final model. An increase in the OFV by \( >6.64 \) (\( P<0.01 \); degrees of freedom =1) was used as the criterion for retaining significant covariate-parameter associations in the model (15).

**Model evaluation.** An internal evaluation method using bootstrap was used to assess the stability and reliability of the final parameter estimates (15). Bootstrap was produced by repeated random sampling with replacement from the original data. This procedure was performed with the software package R (version 3.4.2, http://www.r-project.org). The distribution of weighted residuals for the final model was assessed using histograms and Q-Q plots. The predictive performance of the final model was also assessed by a prediction-corrected visual predictive check Xpose (18) package (version 4.6.1) and R (version 3.4.2).

**Results**

**Data collection.** The data obtained from 17 Chinese pediatric patients with KHE were included in the present analysis. A total of 133 blood concentration values were available for analysis. The patient characteristics and drug combinations are summarized in Tables I and II.
All covariates were evaluated and only the following covariates exhibited a statistically significant effect on the PK parameters: Age, ALT levels and sex. These were included as significant covariates for CL/F, and duration of treatment with sirolimus was included as a significant covariate for V/F. The changes of the OFV are presented in Table III. The final covariate models were as follows: CL/F = θ_{CL/F} x EXP (θ_{AGE} x age) x EXP (θ_{ALT} x ALT) x EXP (θ_{SEX} x sex); V/F = θ_{V/F} x EXP [θ_{DTT} x (DTT/10)]. Where EXP is exponential function, θ_{CL/F} and θ_{V/F} are the typical population values of CL/F and V/F, respectively, θ_{AGE}, θ_{ALT}, θ_{SEX} and θ_{DTT} are the coefficients of the age, ALT, sex and duration of treatment with sirolimus, respectively.
The goodness-of-fit plots of the base population model (Fig. 1) were compared with those of the final model (Fig. 2). Black solid lines represent the line of unity and red smooth lines represent the trend of the points. The closer the red smooth line is to the black solid line, the more predictive the model is. The closer the x- and y-axis values of the same point are, namely, the closer the point is to the y=x line, the closer the population prediction value predicted by the model is to the observed sirolimus blood concentration. The black solid line is the line of unity (the y=x line). The red smooth line represents the trend of the points. Hence, the closer the red smooth line is to the black solid line, the more predictive the model is. (C) $|iWRES|$ vs. individual predictions. $iWRES$ is the difference in the values of the individual prediction and the observation of sirolimus blood concentration. The x-axis value of a point is the individual prediction of sirolimus blood concentration and the y-axis value of a point is the $iWRES$ of the corresponding individual prediction. The smaller the $iWRES$ the better the model predictability. The red smooth line represents the trend of the points. Hence, the closer the red smooth line is to the black solid line (the y=0 line), the more predictive the model is. $iWRES$, individual weighted residuals.
the observed concentrations were within the 95% prediction intervals from the simulation data, indicating that the final model had an improved predictability.

**Discussion**

Sirolimus, an mTOR inhibitor, is expected to be effective in conditions associated with disorders of the mTOR growth control pathway (19). Sirolimus has been widely used in transplantation patients for the prevention of organ allograft rejection, and has been verified to be an effective treatment for PKHE (6-10).

The present study provided the first PPK analysis of sirolimus in Chinese patients with PKHE. Although the TDM data were not originally designed to investigate the PK characteristics of sirolimus, the population approach provides a powerful tool to extract useful information from sparse sampling data (20). Therefore, the present study may help to optimize the use of sirolimus by facilitating the achievement of the desirable therapeutic concentration. In addition, the model of the present study is ethically acceptable for studying pediatric patients, since no excessive blood sampling is required, while a larger amount of blood samples may have been required for traditional PK studies (21). In addition, the sirolimus PPK model in the present study has clinical value in predicting the PK in individual patients with PKHE.

Previously, a developed sirolimus maturation model (22,23) was used to simulate clearance estimates using realistic age and weight covariates for age cohorts aged 0-24 months. In addition,
Mizuno et al (24) reported on model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. The final model included a maturation function for sirolimus clearance and allometrically scaled body weight to account for size differences. However, their models were based on the precondition that the patients had adequate liver and renal functions and did not receive any cytochrome P450 family 3 subfamily A member 4 (CYP3A4) inhibitors or inducers. To explore the influence of demographic features, biological characteristics and concomitant medications on sirolimus CL/F in Chinese patients with PKHE, the present PPK model was built. A one-compartment model with first-order absorption was used to describe the absorption phase. Age, ALT and sex influenced the CL/F, while the duration of treatment with sirolimus influenced the V/F.

Sirolimus is mainly metabolized by the gut mucosa and liver (25,26), and the liver is the major metabolism organ of sirolimus, whose function can affect the drug clearance. In the present study, ALT had an influence on the CL/F of sirolimus, which was similar to the observation regarding the CL/F of tacrolimus reported by Yang et al (27). In addition, growth and development may be investigated using readily observable demographic factors, including weight and age (28). Weight of an individual was selected as a covariate, not body mass index, since Emoto et al (22) and Mizuno et al (23) also selected the weight of an individual as a covariate. Of note, referring to the present study, weight and age exhibited co-linearity and were positively associated. Furthermore, sex and weight also exhibited an association. Numerous studies have demonstrated that the association between drug clearance and body weight in pediatric patients is non-linear and may be well described using allometric scaling (29-31). Size is the primary covariate and may be referenced to a 70-kg person by allometry using a coefficient of 0.75 for clearance (28). The allometric scaling model was assessed in the present study. The present study revealed that body weight is directly associated with sirolimus clearance, and that age and sex are indirect markers. However, the covariates age and sex in combination exhibited smaller OFV and they were, therefore, used in combination in the present study. The present study indicated that CL/F increased with age, and that males had a higher CL/F than females of the same age. This was expected, as infants/children gain weight as their age increases, and males have a higher body weight than females. The present results are essentially consistent with allometric scaling. However, the combination of age and sex is more suitable for modeling the trough concentration data obtained from traditional TDM. Similarly, previous studies have also indicated that patient sex (32) and age (33,34) affect the CL/F of sirolimus. Furthermore, the duration of treatment with sirolimus was significantly associated with the V/F of sirolimus in the present study. One possible explanation is that sirolimus widely distributes in the erythrocytes. As the health of the patients with PKHE recovers, erythrocyte values increase after treatment (Table SI), and this may explain the present observation of the increased V/F with increasing duration of treatment with sirolimus.

In addition, the 17 patients with PKHE in the present study were co-treated with various other drugs: Sulfamethoxazole, methylprednisolone, digoxin, ursodeoxycholic, citidine, omeprazole, fluconazole, cefoperazone/sulbactam and voriconazole. However, no significant drug-drug interactions were identified in the analysis of the PK of sirolimus.

There were several limitations in the present study. First, since only the trough concentration data were available, only a one-compartment model could be applied due to the lack of sufficient informative data regarding drug absorption and distribution. It was not possible to estimate F and the absorption rate constant with a lag time. This is a common modeling method for sparse data processing. In Jiao et al (17), Yang et al (27) and Wang et al (15), it was also not possible to estimate F. Furthermore, Emoto et al (35) reported the impact of CYP3A5*3 polymorphism on sirolimus PK. However, currently, this pharmacogenomic consideration for sirolimus has not been verified in clinical studies. The present study was retrospectively performed using real-world data, which means that genotyping was not routinely performed in the population assessed in the present study. Pharmacogenomic data was also not included in the sirolimus PPK studies by Jiao et al (17) and Wang et al (36). Whether the inclusion of genotyping in the PPK model may better account for the variabilities of sirolimus in patients with PKHE should be investigated. In addition, the limited sample size was due to low incidence, and other studies have used similar group sizes (37). Furthermore, information regarding how large the PKHE lesion was in each patient with treatment time was an evaluation index of pharmacodynamics. Population pharmacokinetics and pharmacodynamics of sirolimus in pediatric patients with KHE will be further established in the future.

In conclusion, the first PPK model of sirolimus in Chinese patients with PKHE was established using retrospective data from a real-world population obtained by routine monitoring. The typical values of CL/F and V/F in the final model were 3.19 l/h and 165 liters, respectively. Age, ALT and sex were included as significant covariates for CL/F, and the duration of treatment with sirolimus was a significant covariate for V/F.
Acknowledgements

Not applicable.

Funding

The present study was supported by the Clinical Pharmacy Key Specialty Construction Project of Shanghai (grant no. YZ2017/5), the Young Medical Talents of Wuxi (grant no. QNRCO20), the Young Project of Wuxi Health and Family Planning Research (grant no. Q201706), the AOSAIKANG Pharmaceutical Foundation (grant no. A201826) and the Wuxi Science and Technology Development Guidance Plan (Medical and Health Care; grant no. CSZON1744).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

ZL conceived and designed the study. DW and XC collected the data and built the model. DW wrote the paper. XC reviewed and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Research Ethics Committee of Children's Hospital of Fudan University without the need for written informed consent, since the data were retrospectively collected without patient identifiers.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.